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Death-associated protein 3 (DAP3) is a molecule with a significant role in the control of both apoptosis and anoikis.
Apoptosis is the predominant type of programmed cell death (PCD) which may occur in response to irreparable
damage to DNA, or in response to induction by inflammatory cells. Anoikis is subset of apoptosis which occurs in
epithelial cells in response to detachment from the surrounding matrix. Both apoptosis and anoikis are of interest in
the context of carcinogenesis. In this review, we shall discuss apoptosis and anoikis, and the recent literature
regarding the role of DAP3 in both these pathways.
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Apoptosis is one of the several mechanisms of pro-
grammed cell death (PCD) which may occur in response
to irreparable damage to DNA, or when induced by in-
flammatory cells. It is an active, ATP dependent process,
as opposed to necrosis, which is a passive process of cell
destruction. It is distinct from necrosis, which may also be
referred to as accidental cell death (ACD). Histologically,
necrosis is characterised by karyolysis and cell swelling,
whilst the stigmata of apoptosis include shrinkage of the
nucleus (pyknosis) and cytosol, with a virtual absence of
inflammation [1,2].
The existence of programmed cell death was initially
proposed by Gluckman (1951) [3]. Further investigation
into cell death discerned at least two distinct patterns. In
addition to the better known necrosis, histological studies
in hepatic ischaemia were suggestive of a so-called ‘shrink-
ing necrosis’, which was distinct from the more typical ne-
crosis [4]. Kerr et al. recognised this to be distinct from
canonical necrosis, coined the term ‘apoptosis’ for this
process, and noted its role in embryogenesis, teratogenesis,* Correspondence: kefahmokbel@hotmail.com
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to hormonal factors [5].
It is suggested that apoptosis and necrosis may be two
extremes of a continuum of cell demise. Deleterious
stimuli of insufficient magnitude to cause necrosis may
cause involution of tissue by way of apoptosis. As noted
above, this was the original context in which apoptosis was
identified [6,7]. The essential distinction between the two
processes has been stated to be that, whilst necrosis is typ-
ically a passive process, apoptosis is an energy-dependent
phenomenon requiring an expenditure of ATP [8].
The processes underlying apoptosis have been impli-
cated in carcinogenesis and have thus been the subject
of continued research in the context of cancer. The
earliest and most well − documented apoptosis gene is
the so-called ‘guardian of the genome’, tumour protein
53 (p53). It was initially identified in animal models in
1979 in association with SV40 large T antigen, and was
dubbed p53 reflecting its molecular weight of 53 kDa
[9,10]. Subsequent studies found it to be over expressed
in cells transformed by chemical carcinogens or ultra-
violet radiation [11-13]. Wild type p53 was found to be a
tumour suppressor, with a role in cell cycle progression,
apoptosis, and the cell response to DNA damage. Muta-
tion of p53 have been implicated in neoplastic trans-
formation in a number of models [11].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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for their role in programmed cell death including, but not
limited to, B-cell lymphoma 2 protein (BCL2), the BCL2
associated X protein (BAX) [14] and those encoding cas-
pases 3, 6, 8 and 9 [15].
Anoikis is a relatively novel area of research in the
field of PCD that has also been of great interest in the
context of carcinogenesis. Specifically, it is the invoca-
tion of apoptosis in response to cell detachment from
the extra cellular matrix (ECM), especially in the context
of parenchymal cells [16].
The ability to survive detachment from the ECM is
prerequisite for the transition to oncogenesis. This
makes anoikis a significant area of interest for cancer re-
search [17].
Our understanding of the apoptosis pathway continues
to evolve. Two major canonical pathways have been iden-
tified, which terminate in a common execution pathway.
In addition, a further pathway bypassing the common exe-
cution cascade is also discussed below. Finally, we shall
also review the literature regarding anoikis and the specific
programmes within apoptosis that contribute to it.
Extrinsic pathway
This pathway is mediated by the activation of trans-
membranous receptors and is commonly induced by
inflammatory cells in response to viral infection or
oncogenesis. These receptors are part of the tumour
necrosis factor receptor (TNFR) super family, six of
whom have been characterised as death receptors (DR).
These receptors have been characterised as type I trans-
membrane protein, with an N-terminal cytoplasmic
terminus. This end of the protein contains an active motif
termed a ‘death domain’ (DD), which interacts with
adapter proteins, thus initiating intra-cellular pathways. In
vivo, the ligands for these receptors have been identified as
TNF-α, the Fas ligand (Fas-L), TNF related apoptosis in-
ducing ligand (TRAIL), as well as other members of the
TNF family. The best documented of these receptors are
TNFR1 and Fas (DR1 and DR2). Others include TRAIL-
R1 and 2 (DR 4 and DR5), and DR3 and DR6 [18].
Death Inducing Signalling Complex (DISC)
The intra-cellular signalling complex for DRs has been
designated as the death inducing signalling complex
(DISC). Broadly speaking, the DR mediates its actions
when activated by interaction with its respective ligand.
The DR typically undergoes trimerisation when thus ac-
tivated. The DD of the receptor interacts with the DD
on the FAS Associated Death Domain (FADD) protein,
which is normally localised in the nucleus. In turn, the
FADD interacts with pro-caspase 8, which is also known as
FADD-like interleukin-1 beta-converting enzyme (FLICE).
These interactions are mediated by corresponding deatheffector domains (DED) on FADD and FLICE, leading to
the activation of the apical caspase 8 [19]. This interaction
is inhibited by FLICE-like inhibitory protein (FLIP), which
competes with FLICE by interacting with FADD [20].
The DISCs of the aforementioned six DRs have small but
significant variations between themselves whilst retaining
the general plan described above. It would be reasonable to
surmise that these variations enable variations in the down-
stream effects of each of the six DRs.
The most significant variation can be seen in the con-
text of FAS and the two TRAIL receptors. In addition to
pro-caspase 8, they also activate pro-caspase 10. The
downstream effects of caspase 10 are believed to be largely
similar to those of caspase 8, thus providing a redundant
signalling pathway [21,22].
Furthermore, the TNFR DISC requires a DD-bearing
adaptor protein in addition to FADD, referred to as
TNFRSF1A-associated via death domain (TRADD).
TRADD is required for FADD-mediated apoptosis. In
addition, TRADD also mediates interactions with TNF
receptor-associated factor 2 (TRAF2), which mediates im-
mune effects of TNF. Specifically, it activates the nuclear
factor of kappa light polypeptide gene enhancer in B-cells
1 (NFKB1), which is involved in the control of genes re-
sponsible for inflammation and immune response [23].
DAP3 and DRs
A similar role in coordinating downstream effects of
DRs is seen in the context of death-associated protein 3
(DAP3). DAP3 is a highly conserved GTP-binding pro-
tein of 4 kDa, encoded by the DAP3 gene located in
chromosome 1 q21 [24]. It is normally kept inactive as
phosphoprotein by the action of protein kinase B (AKT/
PKB). When activated, it co-localises with FADD and
participates in the formation of the DISC [25]. Initially
evidence suggested the DAP3 is involved in the actions
of TNF-α, Fas-L, and TRAIL. However, more recent
studies are suggestive that its association is strongest
with the Fas receptor related DISC. In this context its
actions are enabled by binding with death ligand signal
enhancer (DELE), a relatively novel protein whose
knockdown in HeLa cells was found to inhibit apoptosis
due to TNF- α, Fas or TRAIL (Figure 1) [26].
In a similar fashion, DAP3 was found to mediate inter-
actions between FADD and LKB1 interacting protein 1
(LIP1) in human osteosarcoma cells, which anchors LKB1
to the cytoplasm. This study characterised the expression
of LKB1 to be critical for TRAIL-induced apoptosis medi-
ated by DAP3 on the basis of knock-down studies in
osteosarcoma cells [27]. LKB1 has been previously studied
with regards to its role in Peutz-Jeghers syndrome. It is
characterised as a serine-threonine kinase, with a predom-
inantly tumour-suppressant role in contrast to the mTOR
pathway [28,29].
Figure 1 Schematic representation of the relation of DAP3 and DELE with Fas receptor related DISC. AKT/PKB: protein kinase B, CARD:
caspase activation and recruitment domain, DAP3: death-associated protein 3, DD: death domains, DED: death effector domains, DELE: death
ligand signal enhancer, DR: death receptor, DISC: death inducing signalling complex, FADD: Fas Associated Death, FLICE: FADD-like interleukin-1
beta-converting enzyme, FLIP: FLICE inhibitory protein.
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mediation of anoikis, which is to be discussed at greater
length below [25].
Intrinsic pathway
This pathway is influenced by a large array of non-
receptor factors which may positively or negatively influ-
ence the activation of apoptosis. These factors include
but are not limited to toxins, hormones, viral infections,
physical stimuli and free radicals. The major strand of
this pathway involves the release of mitochondrial con-
tents due to changes in mitochondrial outer membrane
permeabilisation (MOMP) [30].
BCL2 family and control of mitochondrial outer
membrane permeabilisation (MOMP)
MOMP is directly controlled by the BCL2 family of pro-
teins. The BCL2 family of protein are defined by the
presence of BCL2 homology motifs (BH1 to BH4). These
domains were initially seen in BCL2, the archetypical
member of this group of proteins. BCL2 was initially
identified as an oncogene in B-cell lymphoma cells [30].
This was followed by the discovery of BAX, which was
characterised as an anti-oncogenic protein [31]. Since
then, around two dozen members of the BCL2 family
have been identified, with variable tissue expression and
differences in expression of BH domains [32].
Broadly speaking, BCL2 proteins can be classified as
either pro-apoptotic or anti-apoptotic proteins. In turnthe pro-apoptotic molecules are divided into multi-
domain molecules, and BH3-only molecules. A precise
model for the relationship between classes of BCL2 mole-
cules is yet to be devised, with up to four enumerated by
Shamus-din et al. The consensus seems to be that in nor-
mal conditions the multi-domain pro-apoptotic molecules
(BAX, BAK, BOK) are sequestered in combination with
anti-apoptotic molecules (BCL2-like, including BCL-xL,
BCL-w and others). When this pathway is activated, BH3-
only molecules (BID, PUMA, NOXA) bind with the
BCL2-like molecules, allowing the multi-domain pro-
apoptotic molecules to localise to the mitochondrial outer
membrane. BAX/BAK oligomerise to form pores in the
membrane, causing MOMP, which leads to disgorging of
intra-mitochondrial contents [33].
The BH3 molecules have been identified as the control
element of this process. Their expression and activation
seems to be influenced by a variety of stimuli. p53 is the
most significant up stream activator for the BH3 mole-
cules [34,35].
The first wave of mitochondrial apoptogenic agents in-
clude cytochrome c, the second mitochondria-derived
activator of caspase/direct IAP binding protein with low
Pi (SMAC/DIABLO) and high temperature requirement
A2/Omi (HTRA2/OMI).
Cytochrome c and the apoptosome recruitment complex
Cytochrome c interacts with apoptotic protease activat-
ing factor 1 (APAF1) in the presence of ATP or dATP to
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APAF1 has a DD termed the caspase activation and recruit-
ment domain (CARD). [36]. CARD enables interaction with
and activation of pro-caspase 9, leading to the production
of activated caspase 9 [37,38].
Inhibitors of apoptosis proteins (IAPs), SMAC/DIABLO and
HTRA2/OMI
The activation of the caspase cascade has been charac-
terised as an all or none outcome. However, the activation
of caspases is normally prevented by the inhibitors of
apoptosis proteins (IAPs). Upon invocation of the internal
apoptotic pathway, factors sequestered in the mitochon-
dria are released which include, SMAC/DIABLO [39].
SMAC/DIABLO inhibits the activity of IAPs, especially
that of X-linked IAP (XIAP) by sequestering it [40]. Fur-
thermore, Yu et al. suggest that SMAC/DIABLO sensitises
cells to apoptosis induced by PUMA, thus providing a
positive feedback for apoptosis [41]. This may be partially
balanced by a recently described function of XIAP, in
which it impairs the release of SMAC/DIABLO [42].
Similarly, MOMP also leads to the release of HTRA2/
OMI, a serine protease which binds and cleaves various
IAPs [43]. Additionally, a proteome-wide analysis sug-
gests that HTRA2/OMI may also target cytoskeletal
proteins [44].
Mitochondrial DNA-ases
Further mitochondrial contents are then released which
contribute to DNA breakdown. These include apoptosis
inducing factor (AIF) and endonuclease G (EndoG).
AIF binds to DNA in a sequence-nonspecific manner,
inducing chromatin condensation and initiating DNA
breakdown [45,46].
EndoG has been demonstrated to form a complex with
histone H2B and human DNA topoisomerase II alpha
(TOPO2a) after translocation to the cytosol. Whist the
details are as yet undetermined, this complex is be-
lieved to mediate the apoptosis-associated breakdown
of DNA [47].
Pro-survival role of DAP3 in mitochondrial function
Counter-intuitively, DAP3 has a pro-survival role in
mitochondrial function. There are believed to be distinct
intra-mitochondrial and cytosolic pools of DAP3, with
the former resulting from the translocation of the latter
through the mitochondrial membrane. The mitochon-
drial DAP3 forms an important portion of the 28 S sub-
unit of the mitochondrial ribosome, thus essential for
mitochondrial protein synthesis [48]. Furthermore, Kim
et al. reported a deficiency of cytochrome c oxidase 1 in
the mitochondria of Dap3 −/− mouse embryos. As this
is a protein encoded in the mitochondrial genome, itcould be inferred that DAP3 has an integral role in
intra-mitochondrial protein synthesis [49].
The duality seen in the intra-mitochondrial and cyto-
solic roles of DAP3 is not unlike other mitochondrial
proteins, such as cytochrome c and IAP.
PIDDsomes
p53 coordinates DNA repair and may induce apoptosis
via various pathways. In addition to induction of BH3-
only BCL2 proteins, p53 is known to induce the expres-
sion of the protein induced by p53 with a death domain
(PIDD). PIDD forms a complex with the RIP associated
ICH1/CED homologous protein with death domain
(RAIDD). RAIDD is an adaptor protein which also pos-
sesses a CARD motif. This enables it to recruit pro-caspase
2. This complex is referred to as the PIDDsome, and is be-
lieved to mediate apoptosis in response to DNA damage.
The active caspase 2 is formed by conformational changes
in the pro-caspase induced by dimerization. Caspase 2 is an
apical caspase, which activates further components of the
caspase cascade [50,51].
Common execution pathway: the caspase cascade
Intra- and extra-cellular signals converge on a common
pathway which mediates the catabolic processes that
constitute apoptosis. This pathway consists of a cascade
of cysteinyl aspartic acid-protease, commonly referred to
as caspases. Up to 14 have been enumerated in human
and mammalian species [15]. They broadly fall into three
groups:
Apical (Initiators)
As detailed above in relation to the discussions regarding
the relevant recruitment complexes, the apical caspases
include caspases 2, 8, 9, and 10. These pro-enzymes have
DDs, which coordinate the pro-caspases with DISC com-
ponents with similar domains. This interaction induces
dimerization and conformation change in the pro-
caspases, leading to transformation to active caspase, as
well as, auto-activation of the caspases [37,52].
With regards to caspase 8, Scaffidi et al. postulate that
cells may be classified into two types regarding apop-
tosis. Type 1 have been characterised as cell which only
require the action of caspase 8 to undergo apoptosis,
whist type 2 cells which would also require MOMP to
successfully undergo induced cell death [53].
When activated, they cleave downstream caspases, such
as caspases 3 and 7. Also, they further stimulate upstream
apoptosis processes. For instance, caspase 8 is known to
cleave BH3 interacting domain death agonist (BID) to
yield truncated BID (tBID). tBID increases MOMP, thus
further committing the cell towards cell death [54]. Simi-
larly, caspase 8 is known to cleave XIAP [55].
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Caspases 3, 6 and 7 are activated by the apical caspases,
and mediate the effects of the caspase cascade.
Caspase 3 is the most significant of the effector cas-
pases, and can be activated by caspases 8, 9 and 10. It
shares a lot of substrates with caspase 7. When activated,
it mediates breakdown of DNA and of the cytoskeleton,
degradation of XIAP, activation of caspase 6, as well as
activation of the rest of the caspase cascade [56].
Caspase activated DNA-ase (CAD), also known as DNA
fragmentation factor, 40 kDa, beta polypeptide (DFFB),
normally exists in complex with inhibitor of CAD (ICAD).
When activated, caspase 3 cleaves ICAD, leaving CAD un-
impeded to breakdown DNA [57,58]. Upon activation,
caspase 3 is believed to participate in further activation of
the other components in the apoptosis pathway. It cleaves
BID, thus further activating the permeabilisation of the
mitochondrial outer membrane [56].
Caspase 3 also inhibits XIAP, thus further potentiating
the action of caspase 9 [59].
Furthermore, caspase 3 cleaves gelsolin, which has a
role in actin polymerisation and signal transduction [60].
Aminophospholipid translocase normally mediates an
ATP-dependent process in which phosphotidyl serine
(PS) is transferred from the outer layer of cell membrane
to the inner layer. An accumulation of PS on the outer
surface which occurs in the course of apoptosis, marks
the cell for phagocytosis [61]. Studies in erythrocytes im-
plicate caspases 3 and 8 in inactivation of the aminopho-
spholipid translocase [62].
On the other hand, caspase 6 has a distinct substrate
specificity versus caspases 3 and 7 which is currently being
delineated. Of note, caspase 6 is being studied regarding it
avidity for lamin proteins of the nuclear envelop [63].
Inflammatory caspases
Caspase 1, 4, 5, and 11 have been found to have roles in
immune response and innate immunity.
Specifically, they are activated by recruitment complexes
composed of nucleotide-binding domain (NB) and leucine-
rich repeat (LRR) containing receptors (NLR). Especially
noteworthy of this group of proteins are NLRP1 and
NLRP3, which form complexes with adaptor protein
PYDCARD. These complexes are known as inflam-
mosomes. These inflammosomes recruit caspases 1 and 5
respectively [64]. Inflammosomes have been implicated in
immunity and more recently, metabolic syndrome [65].
Similarly, caspase 11 is also recruited by inflammo-
somes in the context of immune response to intracellu-
lar pathogens [66].
Caspase 4 has been implicated in NLR signalling and
the activation of inflammosomes [67,68]. In addition, it also
may be involved in mediation of endoplasmic reticulum
stress related apoptosis [69-71].Perforin/Granzyme pathway
This is a relatively novel pathway utilised by immune
cells in addition to Fas-Fas ligand interactions. In this
case the T and NK cells insert pore molecules into the
cell membrane of the targeted cell, which have been
termed perforins. The perforins interact with intracellular
secretory granules (SGs) which release granule associated
enzymes (granzymes) A and B [72].
Granzyme A activates DNAase NM23-H1, which destroy
nuclear material. This DNAase is normally bound to the
SET complex, which is cleaved by granzyme A leading to
the release and activation of the said DNAase [73].
Granzyme B activates pro-caspases 3 and 10 and
cleaves ICAD. In addition, it activates the intrinsic path-
way by inducing cytochrome c release and by cleaving
BID protein, a member of the BCL2 family [74,75].
Anoikis
Anoikis was initially described by Frisch et al. as apop-
tosis resulting from the detachment of epithelial cells
from surrounding inter-cellular matrix and from sur-
rounding cells. It is believed to be a cellular programme
aimed preservation of normal tissue structure from dis-
ruption by inappropriate cell growth and migration. In
the course of oncogenesis, neoplastic cells would inevit-
ably have to overcome this cellular programme as part
of the epidermal-mesenchymal transition [16].
Our understanding of this cellular programme is cur-
rently evolving. Different cell types require specific integrin
to extracellular matrix (ECM) interactions. Furthermore,
the internal signalling of these interactions into the apop-
tosis pathways may vary between cell types, and are cur-
rently being delineated. These signals are believed to be
largely channelled through the internal apoptosis pathway,
with some involvement of the external pathway, culminat-
ing in the common execution pathway (Figure 2) [76].
Role of the internal pathway in anoikis
The signalling from integrins requires mediation by focal
adhesion kinase (FAK) which is believed to inhibit p53,
which would induce apoptosis if the action of FAK or
contact with ECM were lost. Ilic et al. have determined
that the p53-induced apoptosis is susceptible to inhib-
ition by BCL2 [77,78]. Studies by Chen et al. found that
changes in cell morphology can also induce anoikis, and
that the integrins, FAK and the actin cytoskeleton of the
cell all play roles in anoikis as part of a focal adhesion
complex [79].
Pro-survival signals, including those from anoikis, are
believed to be passed by the extracellular-related kinase
1 and 2 (ERK1/2) and AKT/PKB are known to interact
with BH3 BCL2 proteins, in particular BIM [80]. Similarly,
the RAF pathway, the mitogen/extracellular kinase path-
way (MEK) and MAP kinase pathway are also known to
Figure 2 General scheme illustrating the internal, external and perforin/granzyme pathways within apoptosis, including the sub-
programmes specific to anoikis and DAP3. AKT/PKB: protein kinase B, CARD: caspase activation and recruitment domain, DAP3: death-
associated protein 3, DD: death domains, DED: death effector domains, DELE: death ligand signal enhancer, DR: death receptor, DISC:
death inducing signalling complex, FADD: Fas Associated Death, FLICE: FADD-like interleukin-1 beta-converting enzyme, IPS: 1interferon-β promoter
stimulator 1.
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blasts [81]. Puthalakath et al. have identified a role similar
to that of BIM for BMF in the context of anoikis [82].
Idogawa et al. have characterised BAD as a specific
BH3 molecule for anoikis. Whilst it did not initiate
anokis, it did increase sensitivity to loss of AKT/PKB
signalling [83].
Removal of such signals results in activation of the
BH3 proteins, which sequester the anti-apoptotic BCL2
proteins, thus shift the balance towards BAX-BAK pore
formation and initiation of MOMP, formation of the
apoptosome, and activation of caspase 9 [84].
Role of the external pathway in anoikis, including that of
DAP3
A role for the external pathway in anoikis was proposed
initially by Frisch et al., and has been the subject of
much study. The role of caspase 8 and Fas-DISCs in the
propagation of the apoptosis cascade was identified earl-
ier on [85]. In a study in colonic cells, Grossman et al.characterised the activation of caspase 8 to be a late
event in anoikis, which was not likely to be the initiator
of the cascade [86]. However, more recent studies in
lymphocytes, oesophageal squamous cell and breast can-
cer cells characterise a FAK-caspase 8 axis central to
anoikis signalling [87-89]. Studies in Jurkat cells have
suggested that integrins, specifically β1 integrin, forms a
complex with AKT/PKB, which inhibits pro-caspase 8
via PI3K. Loss of this inhibition is believed to be an initi-
ator for anoikis [90].
The activation of caspase 8 in the context of anoikis
has been associated with interactions with FADD of the
Fas-related DISC. This interaction is inhibited by FLIP,
which competes for FADD. This function of the Fas-
related DISC appears to be ligand-independent [20].
DAP3 has been characterised as critical for anoikis.
Upon the loss of the influence of AKT/PKB, it is de-
phosphorylated and interacts with FADD [25].
The FADD-DAP3 interaction requires the involvement
of interferon-β promoter stimulator 1 (IPS1), which is a
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outer membrane. It is a component of the innate immune
response for viral infections, and communicates with in-
flammatory pathways. IPS1 localises the reaction to the
mitochondrial membrane and recruits pro-caspase 8, thus
triggering the caspase cascade (Figure 3) [91].
Conclusion
Death associated protein 3 and cancer
In conclusion, the current literature places DAP3 at the
nexus of several highly significant and occasionally an-
tagonistic pathways. However, there is scant literature
with regards to its role in human neoplastic disease. It
could be expected that DAP3 would have a tumour sup-
pressant role predicated on its function as a pro-apoptotic
molecule. However, DAP3’s countervailing pro-survival
role in mitochondrial protein synthesis reduces such as-
sumptions to the level of speculation.
Indeed, Mariani et al. reported increased expression
levels of DAP3 in invasive glioblastoma tumour cells and
in glioma cell lines with induced migratory phenotypeFigure 3 Schematic representation of the relation of DAP3 and IPS1 o
activation and recruitment domain, DAP3: death-associated protein 3, DD:
enhancer, DR: death receptor, DISC: death inducing signalling complex, FADD
enzyme, FLIP: FLICE inhibitory protein, IPS: 1interferon-β promoter stimulator 1[92]. These observations could be an instance of a neo-
plastic disease in which the mitochondrial maintenance
prevails over the pro-apoptotic functions of the DAP3.
Furthermore, this could be explained by the fact that P-
loop mutant DAP3 is less effective in inducing apoptosis,
and the COOH-terminal deleted protein (230 amino
acids) acts in a dominant negative fashion, protecting
cells from induced apoptosis [24].
On the other hand, our group has published a clinical
study, in which we examined the mRNA expression of
DAP3 in a breast cancer cohort of 127 patients, with a
median follow-up of 10 years. Specifically we recorded a
strong inverse correlation between mean copy number
of DAP3 and tumour grade, Nottingham Prognostic
Index, clinical stage, and clinical outcome. Furthermore,
Kaplan-Meier analysis shown better survival in the high
transcription group approaching significance [93].
Further investigations would be required to character-
ise the role of DAP3 in human breast cancer. We have
presented our initial findings regarding studies into cell
behaviour of knock-down sub-lines of MCF7 and MDA-n mitochondrial surface. AKT/PKB: protein kinase B, CARD: caspase
death domains, DED: death effector domains, DELE: death ligand signal
: Fas Associated Death, FLICE: FADD-like interleukin-1 beta-converting
.
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of Surgical Oncology in London, and have recently pub-
lished our final results. We found that DAP3 knockdown
sub-lines of MCF7 and MDA-MB‑231 had significantly
increased adhesion and decreased growth when compared
to the controls. Furthermore, invasion and migration were
significantly increased in the MDA-MB-231DAP3kd cells
when compared to controls. The results of the adhesion,
migration and invasion assays are supportive of the hy-
pothesis of DAP3 as a pro-apoptotic antioncogenic pro-
tein, whilst the countervailing effect on growth may be
due to pro-survival role of DAP3 in mitochondrial protein
synthesis [94].
In view of the locus of DAP3 within several cellular
pathways of importance in oncogenesis, we believe that
DAP3 would be a very fruitful avenue for further re-
search. Such research would hopefully engender a better
understanding of underlying pathways, enabling more
discrete therapeutic targeting.Abbreviations
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